MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors
Abstract MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts....
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Data |
| Online Access: | https://doi.org/10.1038/s41597-025-05291-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333716493533184 |
|---|---|
| author | Sarah Dandou Julie A. Vendrell Jérôme Solassol Baptiste Louveau Céleste Lebbé Samia Mourah Florian Rambow Eric Richard Stanislas Du Manoir Alain Mangé Peter J. Coopman Ovidiu Radulescu Romain M. Larive |
| author_facet | Sarah Dandou Julie A. Vendrell Jérôme Solassol Baptiste Louveau Céleste Lebbé Samia Mourah Florian Rambow Eric Richard Stanislas Du Manoir Alain Mangé Peter J. Coopman Ovidiu Radulescu Romain M. Larive |
| author_sort | Sarah Dandou |
| collection | DOAJ |
| description | Abstract MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts. Therefore, we collected data from nine different patient cohorts (total n = 417 patients with advanced melanoma treated with MAPKi) to identify clinical and molecular features. Our curated dataset, named MelanoDB, includes whole or partial exome sequencing data for 191 patients, copy number alteration information for 66 patients, and gene expression data for 132 patients. We provide a web application to explore the integrated dataset and data distribution across the collected studies, and we share this dataset with the scientific community according to the Findable, Accessible, Interoperable, Reusable (FAIR) principles. |
| format | Article |
| id | doaj-art-c8253e40b52b493db0217765bea96f0a |
| institution | Kabale University |
| issn | 2052-4463 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Data |
| spelling | doaj-art-c8253e40b52b493db0217765bea96f0a2025-08-20T03:45:45ZengNature PortfolioScientific Data2052-44632025-07-0112111410.1038/s41597-025-05291-3MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitorsSarah Dandou0Julie A. Vendrell1Jérôme Solassol2Baptiste Louveau3Céleste Lebbé4Samia Mourah5Florian Rambow6Eric Richard7Stanislas Du Manoir8Alain Mangé9Peter J. Coopman10Ovidiu Radulescu11Romain M. Larive12IRCM, Université de Montpellier, ICM, InsermLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de MontpellierIRCM, Université de Montpellier, ICM, InsermDepartment of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de ParisUniversité Paris Cité, AP-HP Dermato-oncology and CIC, Cancer institute AP-HP Nord Paris Cité, INSERM U976, Saint Louis HospitalDepartment of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de ParisDepartment of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital EssenIRCM, Université de Montpellier, ICM, InsermIRCM, Université de Montpellier, ICM, InsermIRCM, Université de Montpellier, ICM, InsermIRCM, Université de Montpellier, ICM, InsermLPHI, Université de Montpellier, CNRSIRCM, Université de Montpellier, ICM, InsermAbstract MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts. Therefore, we collected data from nine different patient cohorts (total n = 417 patients with advanced melanoma treated with MAPKi) to identify clinical and molecular features. Our curated dataset, named MelanoDB, includes whole or partial exome sequencing data for 191 patients, copy number alteration information for 66 patients, and gene expression data for 132 patients. We provide a web application to explore the integrated dataset and data distribution across the collected studies, and we share this dataset with the scientific community according to the Findable, Accessible, Interoperable, Reusable (FAIR) principles.https://doi.org/10.1038/s41597-025-05291-3 |
| spellingShingle | Sarah Dandou Julie A. Vendrell Jérôme Solassol Baptiste Louveau Céleste Lebbé Samia Mourah Florian Rambow Eric Richard Stanislas Du Manoir Alain Mangé Peter J. Coopman Ovidiu Radulescu Romain M. Larive MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors Scientific Data |
| title | MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors |
| title_full | MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors |
| title_fullStr | MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors |
| title_full_unstemmed | MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors |
| title_short | MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors |
| title_sort | melanodb a dataset of clinical and molecular features of patients with advanced melanoma treated with mapk inhibitors |
| url | https://doi.org/10.1038/s41597-025-05291-3 |
| work_keys_str_mv | AT sarahdandou melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT julieavendrell melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT jeromesolassol melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT baptistelouveau melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT celestelebbe melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT samiamourah melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT florianrambow melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT ericrichard melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT stanislasdumanoir melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT alainmange melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT peterjcoopman melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT ovidiuradulescu melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors AT romainmlarive melanodbadatasetofclinicalandmolecularfeaturesofpatientswithadvancedmelanomatreatedwithmapkinhibitors |